| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 681.2MM | +8% |
| Gross Profit | -694.3MM | -307% |
| Cost Of Revenue | 314.8MM | +6% |
| Operating Income | 95.3MM | +5% |
| Operating Expenses | -789.6MM | - |
| Net Income | 1.3B | - |
| R&D | 63.9MM | +47% |
| G&A | 207.1MM | +3% |
| Amortization | 5.7MM | -8% |
| Interest Expense | 12.4MM | -0% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
ATNI, ABR and BIO have been added to the Zacks Rank #5 (Strong Sell) List on April 19, 2023.
The ongoing weakness in the biopharma end markets and tightening of sanctions against Russia is likely to have hurt Bio-Rad's (BIO) first-quarter 2024 growth.
HERCULES, Calif., April 18, 2024--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the first quarter of 2024 on Tuesday, May 7, 2024, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
Investing in stocks inevitably means buying into some companies that perform poorly. Long term Bio-Rad Laboratories...
Bio-Rad's (BIO) margin performance bears the brunt of elevated raw material costs, increased logistics costs and higher employee-related expenses.
OncoCyte details reduced burn rate, Bio-Rad partnership, and growth in the transplant market, alongside a significant net loss in Q4 2023.
Q4 2023 OncoCyte Corp Earnings Call
- Bio-Rad expects to make equity investment in support of deal - Agreement provides for global exclusivity in transplant monitoring commercialization - Bio-Rad granted subsequent investment option upon FDA clearance IRVINE, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced a partnership agreement with Bio-Rad Laboratories (NYSE: BIO), a global leader in life science research and clinical diagnostics products, for the c
Waters (WAT) launches Alliance iS Bio HPLC system to improve efficiency across biopharma QC laboratories, boosting its Waters Operating segment.
HERCULES, Calif., April 10, 2024--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Dr. Andrew Last, Executive Vice President and Chief Operating Officer, is planning to retire by early September of 2024. Dr. Last will remain part of Bio-Rad’s executive leadership team to ensure a smooth transition while the company conducts a search for his successor.